Dicerna Enters Agreement With Roche To Develop And Commercialize DCR-HBVS For The Treatment Of Chronic Hepatitis B Virus (HBV) Infection; Co. To Receive $200M Up Front Plus Up To $1.47B In Milestone Payments
Benzinga Newsdesk